Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | |
| Veröffentlicht: |
Zenodo
2025
|
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.5281/zenodo.17761546 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- <p><span>This study aimed to develop and evaluate improved oral tablets of Glibenclamide, a poorly soluble drug to enhance the drug solubility and dissolution, potentially increasing its bioavailability.<span> </span>Six different formulations were prepared with different ratios of carriers Polyethylene glycol and<span> </span>(PEG 6000 and PVP K-30) were combined with Glibenclamide using various dispersion and evaluated for flowability, compressibility, hardness, friability, disintegration, dissolution, and content. The resulting formulations were assessed for solubility, dissolution rate, compatibility, and crystallinity using various techniques Finally, the most promising formulation (SDF5) was tested in rats to determine its impact on Glibenclamide absorption. All formulations met the required standards, confirming their pharmaceutical equivalence. Compared to the original drug, the solid dispersions showed significantly improved solubility and dissolution. This was attributed to enhanced wettability, dispersability, and reduced crystallinity. Among the carriers, PVP K-30 performed better than PEG 6000 in improving solubility and dissolution. In rats, the SDF5 formulation led to a two-fold increase in Glibenclamide bioavailability compared to the marketed product.</span></p>